TABLE 3.
Log2 fold change in expression of endometrial genes
| Genes | Homozygous compatible | Homozygous incompatible | Heterozygous incompatible |
|---|---|---|---|
| CD28 | .05 ± .34 (a) | .52 ± .65 (a) | 3.01 ± .53* (b) |
| CSF2 | −1.11 ± .45 (a, b) | −1.63 ± .51* (a) | 1.09 ± .88 (b) |
| CTLA4 | .15 ± .54 (a) | .44 ± .76 (a) | 3.37 ± .65* (b) |
| CXCL8 | .13 ± .32 (a) | .79 ± .30 (a) | 1.91 ± .64* (b) |
| FOXP3 | −.16 ± .20 | −.02 ± .18 | .73 ± .68 |
| GATA3 | −.05 ± .17 (a) | −.17 ± .26 (a) | −1.25 ± .48* (b) |
| GNLY | −.25 ± .32 | −.21 ± .31 | .8 ± .26 |
| IFNG | −.32 ± .28 (a) | .51 ± .52 (a) | 2.82 ± .44* (b) |
| IL1A | −.31 ± .34 | .04 ± .15 | 1.04 ± .54 |
| IL2 | −.25 ± .26 | −.06 ± .28 | 1.07 ± .41 |
| IL2RA | .57 ± .22 | .47 ± .26 | .86 ± .22 |
| IL4 | .64 ± .27 | .41 ± .30 | 1.17 ± .50 |
| IL5 | −.14 ± .31 | −.38 ± .32 | −.82 ± .54 |
| IL6 | −.67 ± .41 | −1.16 ± .27 | −.81 ± .58 |
| IL10 | .22 ± .20 (a) | .43 ± .37 (a) | 2.21 ± .58* (b) |
| IL12B | .18 ± .54 (a) | 1.33 ± .68 (a) | 4.17 ± .33* (b) |
| IL13 | −.45 ± .22 | −.61 ± .14 | −.11 ± .49 |
| IL15 | −.17 ± .14 | −.21 ± .06 | .1 ± .24 |
| IL18 | −.01 ± .11 | .37 ± .28 | 1.09 ± .25 |
| IL23A | .30 ± .14 | .11 ± .16 | .33 ± .27 |
| TBX21 | −1.07 ± .59 | −.79 ± .59 | −.04 ± .65 |
| TGFB1 | −.31 ± .14 | −.35 ± .16 | .50 ± .54 |
| TNF | .11 ± .18 (a) | .21 ± .25 (a) | 1.76 ± .51* (b) |
Data are means ± SEM. The data of mRNA expression are normalized to GAPDH and ACTB content and calibrated so that the mean value of the control group equals 1.00. Positive values indicate an increase in transcript abundance; negative values indicate decreased transcript abundance. Different letters within rows indicate a statistical difference between treatment groups. ACTB, β‐actin; GAPDH, glyceraldehyde‐3‐phosphate dehydrogenase; SEM, standard error of mean
*
Statistically different from control group (p < .05).